{"slideshow_credits": null, "snippet": "David Blech, who was once biotechnology\u2019s top gunslinger and was worth about $300 million, is about to begin a four-year prison term, having pleaded guilty to stock manipulation.", "abstract": "David Blech, who was once considered biotechnology\u2019s top gunslinger and was worth about $300 million, is about to begin a four-year prison term, having pleaded guilty to stock manipulation; Blech's downfall reflects maturation of biotechnology from get-rich-quick days to sophisticated, multibillion dollar industry.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/09/06/business/david-blech-a-biotech-king-dethroned.html", "lead_paragraph": "David Blech, who was once biotechnology\u2019s top gunslinger and was worth about $300 million, is about to begin a four-year prison term, having pleaded guilty to stock manipulation.", "headline": {"main": "A Biotech King, Dethroned", "print_headline": "A Biotech King, Dethroned"}, "_id": "522923ea38f0d8740ac9dfef", "word_count": "1433", "multimedia": [{"height": 126, "url": "images/2013/09/06/business/SUBINSIDER/SUBINSIDER-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/09/06/business/SUBINSIDER/SUBINSIDER-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 354, "url": "images/2013/09/06/business/3INSIDER/3INSIDER-articleLarge.jpg", "legacy": {"xlarge": "images/2013/09/06/business/3INSIDER/3INSIDER-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "354"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/09/06/business/jp-INSIDER/jp-INSIDER-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/09/06/business/jp-INSIDER/jp-INSIDER-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-09-06T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Stocks and Bonds", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Celgene Corporation", "name": "organizations", "is_major": "N", "rank": "8"}, {"value": "Blech, David", "name": "persons", "is_major": "Y", "rank": "1"}, {"value": "Sentences (Criminal)", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Biotechnology", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Genetics and Heredity", "name": "subject", "is_major": "N", "rank": "7"}, {"value": "Frauds and Swindling", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Securities and Commodities Violations", "name": "subject", "is_major": "Y", "rank": "9"}], "blog": [], "subsection_name": null, "type_of_material": "News"}